Similar articles for PMID: 29374719

Year	Number of Results
2003	1
2005	2
2006	2
2007	1
2008	4
2009	6
2010	6
2011	6
2012	9
2013	14
2014	15
2015	10
2016	15
2017	23
2018	32
2019	23
2020	15
2021	15
2022	17
2023	8
2024	0

1

Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).

Fujii T, Horiguchi J, Yanagita Y, Koibuchi Y, Ikeda F, Uchida N, Kimura M; GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG). Fujii T, et al. Anticancer Res. 2018 Feb;38(2):905-909. doi: 10.21873/anticanres.12301. Anticancer Res. 2018. PMID: 29374719 Clinical Trial.

2

Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T. Takashima T, et al. Anticancer Res. 2014 Jul;34(7):3583-8. Anticancer Res. 2014. PMID: 24982373 Clinical Trial.

3

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.

Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. Chua C, et al. Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. doi: 10.1007/s00280-015-2811-y. Epub 2015 Jun 24. Cancer Chemother Pharmacol. 2015. PMID: 26099969 Clinical Trial.

4

Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.

Kojima Y, Yoshie R, Kawamoto H, Shimo A, Uejima T, Iwatani T, Motoyoshi A, Kanemaki Y, Boku N, Tsugawa K. Kojima Y, et al. Oncology. 2019;96(6):309-317. doi: 10.1159/000497276. Epub 2019 Mar 20. Oncology. 2019. PMID: 30893699 Clinical Trial.

5

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G. Chan A, et al. Anticancer Res. 2013 Jun;33(6):2657-64. Anticancer Res. 2013. PMID: 23749924 Clinical Trial.

6

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).

Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Gastric Cancer. 2018. PMID: 28936560 Free PMC article. Clinical Trial.

7

Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.

Farhat F, Kattan JG, Ghosn M. Farhat F, et al. Cancer Chemother Pharmacol. 2016 May;77(5):1069-77. doi: 10.1007/s00280-016-3027-5. Epub 2016 Apr 8. Cancer Chemother Pharmacol. 2016. PMID: 27059339 Clinical Trial.

8

A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.

Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, Hirata Y, Sobue S, Mizushima T, Sano H, Mizuno Y, Nakamura M, Hirano A, Tsuchida K, Adachi K, Seno K, Kitagawa M, Kawai T, Joh T. Kataoka H, et al. Cancer Chemother Pharmacol. 2016 May;77(5):957-62. doi: 10.1007/s00280-016-3013-y. Epub 2016 Mar 22. Cancer Chemother Pharmacol. 2016. PMID: 27002325 Clinical Trial.

9

Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

Nakayama T, Morita S, Takashima T, Kamigaki S, Yoshidome K, Ito T, Taguchi T, Sakamoto J, Noguchi S. Nakayama T, et al. Anticancer Res. 2011 Sep;31(9):3035-9. Anticancer Res. 2011. PMID: 21868555 Clinical Trial.

10

A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).

Kagawa S, Muraoka A, Kambara T, Nakayama H, Hamano R, Tanaka N, Noma K, Tanakaya K, Kishimoto H, Shigeyasu K, Kuroda S, Kikuchi S, Kuwada K, Nishizaki M, Shirakawa Y, Fujiwara T. Kagawa S, et al. Cancer Chemother Pharmacol. 2018 Feb;81(2):387-392. doi: 10.1007/s00280-017-3505-4. Epub 2017 Dec 30. Cancer Chemother Pharmacol. 2018. PMID: 29290024 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

190 results

Results by year